Catherine Piveteau

Catherine Piveteau

Auto-generated profile, based on publicly available information

Catherine Piveteau

Univ. Lille, Inserm, Institut Pasteur de Lille, U1177, Drugs and Molecules for Living Systems 3 rue du Pr Laguesse 59000 Lille France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
MFMarion Flipo
Marion Flipo
RFRosangela Frita
Rosangela Frita
MBMarilyne Bourotte
Marilyne Bourotte
MMMaría S. Martínez-Martínez
María S. Martínez-Martínez
MBMarkus Boesche
Markus Boesche
NWNicolas Willand
Nicolas Willand
The sensitivity of Mycobacterium tuberculosis , the pathogen that causes tuberculosis (TB), to antibiotic prodrugs is dependent on the efficacy of the activation process that transforms the prodrugs into their active antibacterial moieties. Various oxidases of M. tuberculosis have the potential to activate the prodrug ethionamide. Here, we used medicinal chemistry coupled with a phenotypic assay to select the N-acylated 4-phenylpiperidine compound series. The lead compound, SMARt751, interacted with the transcriptional regulator VirS of M. tuberculosis , which regulates the mymA operon encoding a monooxygenase that activates ethionamide. SMARt751 boosted the efficacy of ethionamide in vitro and in mouse models of acute and chronic TB. SMARt751 also restored full efficacy of ethionamide in mice infected with M. tuberculosis strains carrying mutations in the ethA gene, which cause ethionamide resistance in the clinic. SMARt751 was shown to be safe in tests conducted in vitro and in vivo. A model extrapolating animal pharmacokinetic and pharmacodynamic parameters to humans predicted that as little as 25 mg of SMARt751 daily would allow a fourfold reduction in the dose of ethionamide administered while retaining the same efficacy and reducing side effects.

19 August 2022 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
VCVirgyl Camberlein
Virgyl Camberlein
CFCharlotte Fléau
Charlotte Fléau
PSPierre Sierocki
Pierre Sierocki
LLLenong Li
Lenong Li
RGRonan Gealageas
Ronan Gealageas
RDRebecca Deprez-Poulain
Rebecca Deprez-Poulain
Endoplasmic reticulum aminopeptidase 2 (ERAP2) is a key enzyme involved in the trimming of antigenic peptides presented by Major Histocompatibility Complex class I. It is a target of growing interest for the treatment of autoimmune diseases and in cancer immunotherapy. However, the discovery of potent and selective ERAP2 inhibitors is highly challenging. Herein, we have used kinetic target‐guided synthesis (KTGS) to identify such inhibitors. Co‐crystallization experiments revealed the binding mode of three different inhibitors with increasing potency and selectivity over related enzymes. Selected analogues engage ERAP2 in cells and inhibit antigen presentation in a cellular context. 4 d (BDM88951) displays favorable in vitro ADME properties and in vivo exposure. In summary, KTGS allowed the discovery of the first nanomolar and selective highly promising ERAP2 inhibitors that pave the way of the exploration of the biological roles of this enzyme and provide lead compounds for drug discovery efforts.

1 January 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NKNicolas Kraupner
Nicolas Kraupner
CDChau Phi DINH
Chau Phi DINH
XWXiaoan Wen
Xiaoan Wen
VLValérie Landry
Valérie Landry
AHAdrien Herledan
Adrien Herledan
RDRebecca Deprez-Poulain
Rebecca Deprez-Poulain

21 December 2022 in Scientific African
Verified
Journal Article
Open access
OSOlivier SAME SONGUE
Olivier SAME SONGUE
CPCatherine Piveteau
Catherine Piveteau
ABAlexandre Biela
Alexandre Biela
RKRichard Kamga
Richard Kamga
BDBenoît Deprez
Benoît Deprez

15 March 2026 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
JBJamal El Bakali
Jamal El Bakali
CRCyril Ronco
Cyril Ronco
VLValérie Landry
Valérie Landry
KPKonstantinos D. Papavasileiou
Konstantinos D. Papavasileiou
MPMichail Papadourakis
Michail Papadourakis
RDRebecca Deprez-Poulain
Rebecca Deprez-Poulain
Insulin-Degrading Enzyme IDE, a zinc metalloprotease that has been associated with Alzheimer 's disease, metabolic diseases and cancer, is an attractive target. Its complex structure, substrate preferences, non-catalytic activities require the development of modulators of this enzyme. While several potent inhibitors are now available, we still lack activators for both in vitro and in vivo explorations of IDE functions and potential application in Alzheimer 's disease. Here we describe the discovery of an original pyrimidine-based series of IDE activators by screening and its structure-activity relationships. Docking studies suggest that compounds may bind the IDE dimer interface, and sterically increase IDE catalytic activity. In vitro and in vivo activities of best activator are consistent with an increase in insulin hydrolysis by IDE in the presence of the activator BDM71230. This compound can serve as a pharmacological tool to explore this intriguing enzyme.

19 August 2022 in Angewandte Chemie
Verified
Journal Article
Open access
VCVirgyl Camberlein
Virgyl Camberlein
CFCharlotte Fléau
Charlotte Fléau
PSPierre Sierocki
Pierre Sierocki
LLLenong Li
Lenong Li
RGRonan Gealageas
Ronan Gealageas
RDRebecca Deprez-Poulain
Rebecca Deprez-Poulain
Endoplasmic reticulum aminopeptidase 2 (ERAP2) is a key enzyme involved in the trimming of antigenic peptides presented by Major Histocompatibility Complex class I. It is a target of growing interest for the treatment of autoimmune diseases and in cancer immunotherapy. However, the discovery of potent and selective ERAP2 inhibitors is highly challenging. Herein, we have used kinetic target‐guided synthesis (KTGS) to identify such inhibitors. Co‐crystallization experiments revealed the binding mode of three different inhibitors with increasing potency and selectivity over related enzymes. Selected analogues engage ERAP2 in cells and inhibit antigen presentation in a cellular context. 4 d (BDM88951) displays favorable in vitro ADME properties and in vivo exposure. In summary, KTGS allowed the discovery of the first nanomolar and selective highly promising ERAP2 inhibitors that pave the way of the exploration of the biological roles of this enzyme and provide lead compounds for drug discovery efforts.